Eli Lilly and Company (Lilly), a global leader in pharmaceuticals, has made headlines with its announcement to acquire Loxo Oncology, a pioneering biopharmaceutical company based in Stamford, Connecticut. The all-cash deal, valued at $8 billion, is poised to significantly enhance Lilly’s oncology portfolio by integrating Loxo Oncology’s cutting-edge precision medicines. A strategic move in oncology […]
Swiss pharmaceutical giant Novartis has officially closed its $2.1 billion acquisition of US-based biopharma company Endocyte, solidifying its position as a leader in radiopharmaceuticals for cancer treatment. The deal, first announced in October 2018, was finalised following shareholder approval earlier this week. A strategic move into radioligand and CAR-T therapies Endocyte specialises in developing radioligand […]
Brooklyn Immuno Therapeutics, a New York-based clinical-stage biopharmaceutical company specializing in cytokine-based cancer therapies, has announced the acquisition of IRX Therapeutics’ assets. The terms of the deal were not disclosed. Brooklyn Immuno Therapeutics, a company focused on developing innovative treatments for cancer, has expanded its portfolio by acquiring IRX Therapeutics. This acquisition positions Brooklyn Immuno […]
Seattle Genetics’ Adcetris, in combination with CHP chemotherapy, gains FDA approval for treating certain types of peripheral T-cell lymphoma. Seattle Genetics has announced that the U.S. Food and Drug Administration (FDA) has granted approval for its monoclonal antibody Adcetris (brentuximab vedotin) in combination with CHP chemotherapy (cyclophosphamide, doxorubicin, prednisone). This new approval is specifically for […]
Swiss pharmaceutical company Novartis has announced a strategic acquisition of the US-based biopharma firm Endocyte for approximately $2.1 billion. This move aims to bolster Novartis’s capabilities in radiopharmaceuticals, particularly for cancer treatment. The acquisition will see Novartis purchase all outstanding shares of Endocyte at $24 per share. Expanding Expertise in Radiopharmaceuticals Endocyte specializes in developing […]
AstraZeneca has achieved a major regulatory milestone with the US Food and Drug Administration (FDA) approval of Lumoxiti (moxetumomab pasudotox-tdfk), a CD22-directed cytotoxin for the treatment of relapsed or refractory hairy cell leukemia (HCL). This approval marks a significant advancement in the treatment of this rare and chronic form of leukemia, offering new hope to […]
Merck has achieved a significant milestone by obtaining approval from the European Commission (EC) for its cancer immunotherapy, Keytruda (pembrolizumab), to be used in combination with Eli Lilly’s chemotherapy drug pemetrexed (ALIMTA) and platinum chemotherapy. This approval specifically targets the first-line treatment of metastatic nonsquamous non-small cell lung cancer (NSCLC) in adults who do not […]
Irish biopharmaceutical company Alkermes has announced an expansion of its ongoing Phase 1 trial to evaluate the safety and anti-tumor activity of its immuno-oncology drug ALKS 4230 in combination with Merck’s PD-1 inhibitor KEYTRUDA (pembrolizumab). This trial aims to explore the potential of this combination therapy in treating advanced solid tumors. ALKS 4230 is an […]
In an ambitious move within the biotechnology sector, a new U.S. biotech company, Twentyeight-Seven Therapeutics (28-7), has been established in Cambridge with a primary focus on developing therapies for cancer and other diseases by modulating non-coding RNA (ncRNA). Coinciding with its launch, Twentyeight-Seven Therapeutics announced a successful $65 million Series A financing round led by […]
The Janssen Pharmaceutical Companies of Johnson & Johnson have achieved a significant milestone with the European Commission’s approval of Darzalex (daratumumab) for use as an initial therapy in adult patients with newly diagnosed multiple myeloma who are not eligible for autologous stem cell transplant (ASCT). This approval allows for the combination of daratumumab with bortezomib, […]